Physician profile
Hamsa Gabbara
NPI 1083234777
$3,184.78
in general payments reported to CMS, 2019-2025
37 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $113 · 2024: $1,294 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $471.39 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $316.99 | 2024-2025 | Korlym |
| Abbvie INC. | $307.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $256.93 | 2024-2025 | Breztri, Seroquel, Airsupra |
| Lilly USA, LLC | $224.37 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $178.47 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.35 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $146.77 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $95.31 | 2024-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $91.18 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.84 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $87.80 | 2024-2025 | Sunosi, Auvelity, Symbravo |
| Astellas Pharma US INC | $84.24 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $64.69 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $64.04 | 2024-2025 | Trelegy Ellipta, Arexvy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.55 | 2024-2025 | |
| Ucb, INC. | $45.31 | 2025 | Nayzilam |
| Exact Sciences Corporation | $40.95 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $40.76 | 2024 | Watchman Flx |
| Aimmune Therapeutics, INC. | $32.69 | 2025 | Zenpep |
| Lundbeck LLC | $31.30 | 2024 | Vyepti |
| Sanofi-Aventis U.S. LLC | $28.19 | 2024 | |
| Dexcom, INC. | $28.01 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $26.18 | 2024-2025 | Voquezna |
| United Therapeutics Corporation | $20.67 | 2025 | Tyvaso |
| Seqirus USA INC | $19.46 | 2025 | Fluad, Flucelvax |
| Alnylam Pharmaceuticals INC. | $18.92 | 2024 | Amvuttra |
| Krystal Biotech INC | $17.89 | 2025 | Vyjuvek |
| Averitas Pharma INC. | $17.33 | 2024 | Qutenza |
| Neurocrine Biosciences, INC. | $16.80 | 2024 | Ingrezza |
| Cequr Corporation | $16.79 | 2025 | Cequr Simplicity |
| Shield Therapeutics INC | $15.23 | 2024 | |
| Verona Pharma, INC. | $15.20 | 2025 | Ohtuvayre |
| Amgen INC. | $15.20 | 2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $14.61 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.32 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $13.18 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamsa Gabbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.